ALSO NOTED: CMC to boost production at Bothell facility; Eisai buys antibody; Vectura pockets milestone, equity pay; and much m

> The Copenhagen-based CMC Biopharmaceuticals says it plans to increase production of therapeutic proteins after buying the former Icos's plant in Bothell. Icos was acquired at the beginning of the year by Eli Lilly. Report

> Japan's Eisai has acquired the rights to an antibody therapy for Alzheimer's from Sweden's BioArtic Neuroscience. Report

> Skystar BioPharmaceutical has established a new research and development center in Shanghai. Release

> Vectura Group has picked up €15 million from a milestone payment and equity investment by Boehringer Ingelheim. Report

> Biomarin Pharmaceutical and IGAN Biosciences have started to develop an IgA protease for treating kidney disorder. Report

> Blocking a single critical protein reversed the effects of aging on the skin of mice, suggesting that researchers may be on to a short-term therapy that could help older people heal from an injury. Report

> Scientists at Johns Hopkins were able to damaged skulls by transplanting human embryonic stem cells directly to the site of massive injuries. Report

> Merck issued its initial earnings outlook for 2008 today, and in it specifies Fosamax sales at $1.1 billion to $1.4 billion, down from $2.9 billion to $3.1 billion in 2007. Report

> Look, world--our house-cleaning is working. That's what China's drug regulators are saying today with a new, statistics-filled report. Report

And Finally... In one of the most closely watched research programs at a biotech company, Sirtris has unveiled three new chemicals that could play a big role in fighting the effects of aging and resisting diabetes. Report

Suggested Articles

With its $400 million Fund XII, Atlas Venture became the latest VC shop to close a major fund since the WHO officially declared COVID-19 a pandemic.

A few years ago, one of our Fierce editors met a Big Pharma R&D chief for the first time. “You’re the ones with the scary name,” he joked.

Pfizer's eczema hopeful has been building its case to challenge Sanofi and Regeneron's Dupixent, but safety issues could stand in its way.